Compare IQIYI Inc - ADR (IQ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Moderna, Inc. — how do they compare? IQIYI Inc - ADR trades at $1.35 (market cap $1.30B), while Moderna, Inc. trades at $62.24 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 18.6× IQIYI Inc - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| IQ | MRNA | |
|---|---|---|
Market Cap | $1.30B | $24.18B |
Sector | Media | Health |
52-Week High | $2.79 | $81.80 |
52-Week Low | $0.96 | $22.36 |
Enterprise Value | $2.88B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.36, up 2.26% today, with a bullish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion. Valuation ratios show a high P/E of 144.05 but attractive P/S of 0.33 and P/B of 0.67. Recent news highlights AI platform growth and leadership changes, with Q2 2026 earnings due August 18, 2026.
The outlook is mixed: analyst consensus is 50% buy, but profitability challenges and revenue declines pose risks. Upside potential exists from AI initiatives and cost controls, yet competitive pressures and regulatory uncertainty in China remain headwinds. The stock offers speculative value for turnaround bets, balanced by fundamental weaknesses.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
